Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88


Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ.

Andersson S, Mints M, Wilander E.

Oncol Lett. 2013 Jul;6(1):215-219. Epub 2013 May 15.


Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.

Simonella LM, Lewis H, Smith M, Neal H, Bromhead C, Canfell K.

BMC Infect Dis. 2013 Mar 3;13:114. doi: 10.1186/1471-2334-13-114.


Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.


Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears.

Derchain SF, Rabelo-Santos SH, Sarian LO, Zeferino LC, de Oliveira Zambeli ER, do Amaral Westin MC, de Angelo Andrade LA, Syrjänen KJ.

Gynecol Oncol. 2004 Dec;95(3):618-23.


Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.

Leinonen MK, Nieminen P, Lönnberg S, Malila N, Hakama M, Pokhrel A, Laurila P, Tarkkanen J, Anttila A.

BMJ. 2012 Nov 29;345:e7789. doi: 10.1136/bmj.e7789.


HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix.

Quint KD, de Koning MN, van Doorn LJ, Quint WG, Pirog EC.

Gynecol Oncol. 2010 May;117(2):297-301. doi: 10.1016/j.ygyno.2010.02.003. Epub 2010 Mar 6.


Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S78-84. doi: 10.1097/LGT.0b013e31828543c5.


Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix.

Costa S, Negri G, Sideri M, Santini D, Martinelli G, Venturoli S, Pelusi C, Syrjanen S, Syrjanen K, Pelusi G.

Gynecol Oncol. 2007 Jul;106(1):170-6. Epub 2007 May 4.


HPV-genotypes in high-grade intraepithelial cervical lesions in Danish women.

Kirschner B, Schledermann D, Holl K, Rosenlund M, Raillard A, Quint W, Molijn A, Jenkins D, Junge J.

Acta Obstet Gynecol Scand. 2013 Sep;92(9):1032-40. doi: 10.1111/aogs.12162. Epub 2013 Jun 1.


Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions.

Miller RA, Mody DR, Tams KC, Thrall MJ.

Arch Pathol Lab Med. 2015 Nov;139(11):1431-6. doi: 10.5858/arpa.2014-0633-OA. Epub 2015 May 7.


Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.

Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, Poppe W.

BJOG. 2006 Nov;113(11):1303-7. Epub 2006 Sep 15.


Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia.

Quek SC, Lim BK, Domingo E, Soon R, Park JS, Vu TN, Tay EH, Le QT, Kim YT, Vu BQ, Cao NT, Limson G, Pham VT, Molijn A, Ramakrishnan G, Chen J.

Int J Gynecol Cancer. 2013 Jan;23(1):148-56. doi: 10.1097/IGC.0b013e31827670fd.


Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact.

Pérez-Castro S, Lorenzo-Mahía Y, Iñarrea Fernández A, Lamas-González MJ, Sarán-Díez MT, Rubio-Alarcón J, Reboredo-Reboredo MC, Mosteiro-Lobato S, López-Miragaya I, Torres-Piñón J, Melón-García S.

Enferm Infecc Microbiol Clin. 2014 Oct;32(8):479-85. doi: 10.1016/j.eimc.2013.09.011. Epub 2013 Nov 22.


Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.

Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Review. Erratum in: Vaccine. 2013 Dec 16;31(52):6266.


Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial.

Monsonego J, Cox JT, Behrens C, Sandri M, Franco EL, Yap PS, Huh W.

Gynecol Oncol. 2015 Apr;137(1):47-54. doi: 10.1016/j.ygyno.2015.01.551. Epub 2015 Feb 8.


Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.

Castle PE, Shaber R, LaMere BJ, Kinney W, Fetterma B, Poitras N, Lorey T, Schiffman M, Dunne A, Ostolaza JM, McKinney S, Burk RD.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):946-53. doi: 10.1158/1055-9965.EPI-10-1267. Epub 2011 Mar 17.


Oncogenic human papillomavirus-infected immature metaplastic cells and cervical neoplasia.

van der Marel J, van Baars R, Alonso I, del Pino M, van de Sandt M, Lindeman J, ter Harmsel B, Boon M, Smedts F, Ordi J, Torné A, Jenkins D, Quint W.

Am J Surg Pathol. 2014 Apr;38(4):470-9. doi: 10.1097/PAS.0000000000000174.


The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.


Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE.

Lancet Oncol. 2011 Jul;12(7):663-72. doi: 10.1016/S1470-2045(11)70145-0. Epub 2011 Jun 16. Erratum in: Lancet Oncol. 2011 Aug;12(8):722.

Supplemental Content

Support Center